Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab Induction in Ulcerative Colitis (LUCENT 1)
NCT03518086Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 35
01
Overview
A Phase 3 trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Started Jun 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03518086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518086.